← Oncology Approval Tracker

FDA DECISION ·

Amtagvi

lifileucel · Iovance Biotherapeutics

Accelerated approvalNew therapyMelanoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with unresectable or metastatic melanoma after a PD-1 blocker and, if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor.

LAMPGEN ANALYSIS

Why it matters

This tumor-infiltrating lymphocyte therapy brings an individualized cell product to the post-checkpoint melanoma setting.

What research teams should watch

Coordinate tumor procurement, manufacturing, lymphodepletion and post-infusion interleukin-2 support across teams.

PRIMARY RECORDS

Sources